Psilocybin at the heart of a pioneer study in France

Research on psychedelic substances has a renewed interest in the medical field. At the heart of this therapeutic revolution, psilocybin, a molecule resulting from hallucinogenic mushrooms, is the subject of an innovative study in France. The University Hospital Center (CHU) of Nîmes is positioned at the forefront of this scientific exploration, opening up new perspectives in the treatment of complex pathologies such as dependence on thealcohol and resistant depression

Context of the study on psilocybin

A scientific renewal

The interest in the therapeutic properties of psilocybin is not new. However, after decades of prohibition, research on this substance experiences a significant renewal. The Nîmes University Hospital, by launching this experimentation, is part of a global movement to reassess the medical potential of psychedelics.

Research objectives

The study mainly aims to assess the effectiveness of psilocybin in the treatment of two particularly worrying conditions:

• Alcohol dependence
• Depression resisting conventional treatments

These pathologies, often resistant to classic therapeutic approaches, represent a major challenge for modern psychiatry.

Hallucinogenic fungi to treat alcoholism, an unprecedented experience was launched at the Nîmes University Hospital, video the mag of health on France5

Experimental methodology

Rigorous protocol

The experiment carried out in Nîmes is characterized by a rigorous scientific protocol. Selected patients are subject to a strict framework, guaranteeing their safety throughout the process.

Integration of psychotherapy

One crucial aspect of the study lies in the association of taking psilocybin with psychotherapy sessions. This combined approach aims to maximize the potential benefits of treatment, by providing psychological support before, during and after psychedelic experience.

Therapeutic potential of psilocybin

Action mechanisms

Psilocybin acts on the serotonergic system of the brain, causing temporary changes to consciousness. These neurochemical changes could cause its potential therapeutic effects.

Promising preliminary results

Although the study is still in progress, the first feedback is encouraging. Some patients report significant improvement in their condition, with a decrease in depressive symptoms and a reduction in alcohol consumption

Research issues and challenges

Legal and ethical framework

Public perception

Future prospects

Application of applications

If the results of the study prove to be conclusive, one could consider the expansion of the therapeutic applications of psilocybin to other psychiatric disorders, such as post-traumatic stress or chronic anxiety.

To personalized medicine

The approach combining psilocybin and psychotherapy opens the way to a more personalized medicine in psychiatry. Each patient could benefit from a treatment suitable for their specific situation, thus maximizing the chances of healing.

Testimonials on the use of psilocybin to treat alcoholism

As part of the clinical trial conducted at the Grau-du-Roi addictology center, several patients shared their experiences with psilocybin in the treatment of alcoholism. Among them, John, a man in their fifties and father of three, agreed to tell his journey.

John's story

John suffered from severe alcoholism and decided to participate in this innovative study. During the four weeks spent in the center, he experienced sessions where psilocybin was administered in a secure therapeutic setting.

The effects of sessions

John describes his experiences as intense "trips" which allowed him to explore deep aspects of his psyche. He evokes a significant awareness concerning his relationship to alcohol and the reasons which led him to this dependence. These sessions offered him a space to reflect on his behaviors and his emotions.

Returns after five months

Five months after completing the program, John shares that the effects of psilocybine therapy has continued. He feels more in control of his life and has managed to considerably reduce his consumption of alcohol. He underlines the importance of psychological support also calling 'set and setting' which accompanied the sessions, thus allowing integration of lived experiences.

A message of hope

John's testimony illustrates the therapeutic potential of psilocybin in the treatment of alcoholism. His experience highlights not only the immediate effects of psychedelic, but also their ability to induce lasting changes in the perception and behavior of patients.
This feedback is part of a broader approach aimed at reassessing the treatments available for people with dependence, emphasizing innovation and mental health research.

The risks and precautions associated with the use of hallucinogenic fungi

Although the results are positive, it is important to emphasize that psilocybin is not a miracle solution, health professionals must supervise the use of hallucinogenic mushrooms for therapeutic purposes. In France, the consumption of psilocybin without medical prescription present of the dangers for health. Of the complications medical as hypertension may occur and must be treated by health professionals.

Psychotherapy in the use of psychedelics

It is necessary to adopt a holistic approach which integrates the psychotherapy when it comes to using hallucinogenic mushrooms in a context therapeutic. Patients who participate in the Nîmes CHU study receive assistance throughout their psychedelic treatment. THE patients Receive detailed explanations on the processing of treatment before the sessions and discuss their intentions with the caregivers. Patients are hospitalized for four weeks during the sessions in order to benefit of a follow up in -depth and prevent complications related to weaning alcohol.

We are present at any time next to the patient: he can feel more or less intense things, with sometimes revival of difficult times, or anxiety.

Dr Amandine Luquiens, psychiatrist addictologist at the Nîmes University Hospital.

 

According to Amandine Luquiens, psychiatrist addictologist at the Nîmes University Hospital, this approach promotes the neurogenesis by stimulating the Growth of neurons and in improving there communication between different regions of brain, which can help to modify of the behavior frozen as addictive disorders or depression. Combined with traditional psychotherapy care, the use of psilocybin would allow patients to learn more quickly to change their behavior, thus offering promising prospects to prevent relapses.

The goals of the study are as follows:

This pilot study aims to assess the feasibility, acceptability, THE mechanisms action and the preliminary results of the effectiveness psychotherapy Assisted by psilocybin in the treatment of AUD with signs of depression after weaning, in addition to the usual treatment.

The procedures used:

An experimental study will be conducted at the Nîmes University Hospital with 30 people with alcohol -related problems with symptoms of depression and having left alcohol recently. Participants will be divided randomly into two groups :

1. 250 mcg of psilocybine twice over a period of 3 weeks
2. Very low dose of 10 mcg of psilocybin in similar conditions, with close psychotherapeutic supervision in addition to the usual treatment.

The study will evaluate not only acceptability and feasibility of treatment, but also study methods, comparing the two groups chosen. In addition, it will examine the preliminary efficiency of psychotherapy assisted by psilocybin in the treatment of patients with autism with persistent signs.

Conclusion

The experiment carried out at the Nîmes University Hospital on the therapeutic use of psilocybin marks a turning point in psychiatric research in France. It is part of a global movement to reassess the medical potential of psychedelic substances. Although the final results are still expected, this pioneering study opens up promising perspectives for the treatment of complex pathologies such as alcohol dependence and resistant depression.

** FAQ **

What is psilocybin?

Psilocybin is a chemical compound present in certain hallucinogenic mushrooms, also called magic mushrooms. It is known for its psychedelic effects and has been traditionally used in ritual and spiritual contexts.

What are the effects of psilocybin on the brain?

Psilocybin acts mainly by linking to serotonin receptors in the brain, which leads to alterations of perception, consciousness and mood. It can induce intense psychedelic experiences, characterized by changes in perception, creative thoughts and intense emotions.

Is psilocybine legal in France?

In France, psilocybin is classified as an astonishing substance and is therefore illegal to own, cultivate or distribute. However, exceptions can be done in the context of approved scientific research.

What are the potential advantages of psychotherapy assisted by psilocybin?

Psychotherapy assisted by psilocybin offers several potential advantages, including rapid and durable therapeutic effects, an improvement in emotional regulation and a reduction in depressive symptoms and anxiety.

What are the risks associated with the use of psilocybin?

The use of psilocybin has certain risks, such as intense psychedelic experiences and unpredictable reactions in some people. It is important to conduct rigorous clinical studies and provide adequate psychotherapeutic support to minimize these risks.

What are the future prospects for research on psychedelics in France?

Research on psychedelics in France is booming, with more and more studies exploring their therapeutic potential. It is likely that new research will continue to deepen our understanding of psychedelics and their applications in the field of mental health.

Is psychotherapy assisted by psilocybin accessible to the general public in France?

Currently, psychotherapy assisted by psilocybin is still in the clinical research phase and is not accessible to the general public in France. However, the results of these studies could possibly lead to changes in the regulations and more accessibility of this form of therapy.

What are the other psychedelic substances studied in France?

In addition to psilocybin, other psychedelic substances such as LSD and Ayahuasca are also studied in France for their potential therapeutic effects. These substances are the subject of in -depth research to better understand their action mechanisms and their clinical applications.

What are the expected results of the study conducted in France on psychotherapy assisted by psilocybin?

The expected results of the study in France could provide additional evidence of the therapeutic potential of psilocybin in the treatment of alcoholism and depression. These results could contribute to greater acceptance and more widespread use.

Is it possible to participate in a study on psychotherapy assisted by psilocybin in France?

If you are interested in participating in a study on psychotherapy assisted by psilocybin in France, it is recommended to find out with research institutions and clinical centers that carry out these studies. They will be able to provide you with information on the selection criteria and the procedures to become a study in a study.

Never forget:

• This article is only intended for informative purposes and in no way replaces professional medical advice.
• Never consume hallucinogenic mushrooms without the opinion and supervision of a qualified health professional.

Source: https://www.chu-nimes.fr/actu-cht/etude-pad.html